EyePoint (EYPT) Pharmaceuticals announced it has enrolled and randomized over 400 patients in the Phase 3 LUGANO pivotal trial of DURAVYU for the treatment of wet age-related macular degeneration exceeding its enrollment target. The seven-month enrollment for LUGANO represents one of the fastest enrolling Phase 3 pivotal trials for wet AMD to date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target lowered to $26 from $30 at Mizuho
- EyePoint reports inducement grants under NASDAQ listing rule
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
- EyePoint Pharma’s Promising Q1 2025 Financial Results
- EyePoint Pharma’s Earnings Call Highlights Positive Momentum